FOLH1 and neoplasm: A head-to-head comparison of a 177Lu-labeled-PSMA-targeting ligand containing 4-(p-iodophenyl)butyric acid (CTT1403) in PC3-PIP tumor-bearing mice revealed higher tumor uptake (~47 %IA/g at 72 h p.i.)and longer retention in the tumor than the compound minus the albumin-binding entity (~1 %IA/g at 72 h p.i.), but also, kidney retention was increased (~48 %IA/g and ~7 %IA/g at 72 h p.i., respectively) [132].